Fuzzy Handling of Uncertainties in Modeling the Inhibition of Glycogen Synthase Kinase-3 by Paullones

We consider the problem of modeling the biological activity of inhibitors (belonging to the paullone family) for Glycogen Synthase Kinase-3 (GSK-3). The development of a nonlinear model that establishes the quantitative structure-activity relationship (QSAR) involves an uncertainty regarding the optimal choice of molecular descriptors, structure of the model, number of free model parameters, and so on. This study advocates the use of a fuzzy filter, that mathematically takes into account the underlying uncertainties, for the handling of the uncertainties. The modeling performance is prevented from being adversely affected by the uncertainties with the help of a fuzzy filter. We demonstrate that a robustness of the modeling performance against uncertainties could be achieved using the proposed approach.

[1]  Norbert Stoll,et al.  An energy-gain bounding approach to robust fuzzy identification , 2006, Autom..

[2]  L. Meijer,et al.  Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. , 1999, Journal of medicinal chemistry.

[3]  D. Manallack,et al.  Neural networks in drug discovery: Have they lived up to their promise? , 1999 .

[4]  Norbert Stoll,et al.  A min-max approach to fuzzy clustering, estimation, and identification , 2006, IEEE Transactions on Fuzzy Systems.

[5]  Larry Chen,et al.  Automatic Facial Expression Recognition from Video Sequences Using Temporal Information Table of Contents , 2000 .

[6]  G L Snyder,et al.  Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. , 2000, European journal of biochemistry.

[7]  K. Thurow,et al.  Robust fuzzy mappings for QSAR studies. , 2007, European journal of medicinal chemistry.

[8]  H. Eldar-Finkelman,et al.  Glycogen synthase kinase 3: an emerging therapeutic target. , 2002, Trends in molecular medicine.

[9]  David J. C. MacKay,et al.  Bayesian Interpolation , 1992, Neural Computation.

[10]  Mercedes Alonso,et al.  Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation , 2002, Medicinal research reviews.

[11]  L. Meijer,et al.  Evaluation and comparison of 3D-QSAR CoMSIA models for CDK1, CDK5, and GSK-3 inhibition by paullones. , 2004, Journal of medicinal chemistry.

[12]  Philip Cohen,et al.  GSK3 takes centre stage more than 20 years after its discovery. , 2001 .

[13]  Frank R. Burden,et al.  Use of Automatic Relevance Determination in QSAR Studies Using Bayesian Neural Networks , 2000, J. Chem. Inf. Comput. Sci..

[14]  F. Burden,et al.  Robust QSAR models using Bayesian regularized neural networks. , 1999, Journal of medicinal chemistry.

[15]  F. Burden,et al.  New QSAR Methods Applied to Structure—Activity Mapping and Combinatorial Chemistry. , 1999 .

[16]  Michel Goedert,et al.  GSK3 inhibitors: development and therapeutic potential , 2004, Nature Reviews Drug Discovery.

[17]  David A Winkler,et al.  Neural networks as robust tools in drug lead discovery and development , 2004, Molecular biotechnology.